Skip to main content

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Latest News

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance
HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI ResistanceNews & Conference Highlights

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

May 6, 2026
EGFR-Mutated NSCLC: Acquired Resistance
EGFR-Mutated NSCLC: Acquired ResistanceNews & Conference Highlights

EGFR-Mutated NSCLC: Acquired Resistance

May 6, 2026
Top 5 Highlights From ELCC 2026
Top 5 Highlights From ELCC 2026News & Conference Highlights

Top 5 Highlights From ELCC 2026

May 4, 2026

Latest News

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance
HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI ResistanceNews & Conference Highlights

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

May 6, 2026
EGFR-Mutated NSCLC: Acquired Resistance
EGFR-Mutated NSCLC: Acquired ResistanceNews & Conference Highlights

EGFR-Mutated NSCLC: Acquired Resistance

May 6, 2026
Top 5 Highlights From ELCC 2026
Top 5 Highlights From ELCC 2026News & Conference Highlights

Top 5 Highlights From ELCC 2026

May 4, 2026

Expert Insights

View All

High-level synthesis, interpretation, and clinical framing from established thought leaders.

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Navigating Second-Line Treatment Decisions in EGFR+ NSCLCExpert Insights

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC

April 1, 2026
The Future of EGFR+ NSCLC Management
The Future of EGFR+ NSCLC ManagementExpert Insights

The Future of EGFR+ NSCLC Management

March 30, 2026
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLCExpert Insights

How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC

March 26, 2026
Promoting Treatment Adherence and Managing AEs in EGFR+ NSCLC
Promoting Treatment Adherence and Managing AEs in EGFR+ NSCLCExpert Insights

Promoting Treatment Adherence and Managing AEs in EGFR+ NSCLC

March 23, 2026

News & Conference Highlights

View All

Rapid, curated interpretation of emerging data.

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance
HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI ResistanceNews & Conference Highlights

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

May 6, 2026
EGFR-Mutated NSCLC: Acquired Resistance
EGFR-Mutated NSCLC: Acquired ResistanceNews & Conference Highlights

EGFR-Mutated NSCLC: Acquired Resistance

May 6, 2026
Top 5 Highlights From ELCC 2026
Top 5 Highlights From ELCC 2026News & Conference Highlights

Top 5 Highlights From ELCC 2026

May 4, 2026
EGFR-Mutated NSCLC Frontline Treatment
EGFR-Mutated NSCLC Frontline TreatmentNews & Conference Highlights

EGFR-Mutated NSCLC Frontline Treatment

May 4, 2026

Emerging Voices in EGFR Care

View All

Highlight next-generation oncologists with fresh, pragmatic viewpoints.

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MScEmerging Voices in EGFR Care

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

November 14, 2025

How I Treat

View All

Practical, case-based, scenario-based, decision-oriented content.

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy
EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination TherapyHow I Treat

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy

April 28, 2026
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line TreatmentHow I Treat

EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

April 28, 2026
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved CaseHow I Treat

EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case

April 21, 2026
Future Directions and Unmet Needs in in EGFR-Mutant NSCLC
Future Directions and Unmet Needs in in EGFR-Mutant NSCLCHow I Treat

Future Directions and Unmet Needs in in EGFR-Mutant NSCLC

April 21, 2026

Clinical Updates Calendar

Mo
Tu
We
Th
Fr
Sa
Su
Anticipated Decisions
Approvals
Conferences
Data Readouts
Designations
Events This Month

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

© 2026 MJH Life Sciences. All rights reserved.

Home
Clinical Updates Calendar
View All Resources